"Jan. 4, 2013 -- A new study from Australia may offer a new way of identifying people at risk of glaucoma years before vision loss happens.
Glaucoma is a leading cause of blindness. But because vision damage often occurs gradually, mos"...
- Patient Information:
Details with Side Effects
ACUVAIL® ophthalmic solution is indicated for the treatment of pain and inflammation following cataract surgery.
DOSAGE AND ADMINISTRATION
One drop of ACUVAIL® should be applied to the affected eye twice daily beginning 1 day prior to cataract surgery, continued on the day of surgery, and through the first 2 weeks of the postoperative period.
Use With Other Topical Ophthalmic Medications
ACUVAIL® ophthalmic solution may be administered in conjunction with other topical ophthalmic medications such as alpha-agonists, beta-blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics. Drops should be administered at least 5 minutes apart.
Dosage Forms And Strengths
- 30 single-use vials filled with 0.4 mL of ketorolac tromethamine ophthalmic solution, 0.45% (4.5 mg/mL)
- 60 single-use vials filled with 0.4 mL of ketorolac tromethamine ophthalmic solution, 0.45% (4.5 mg/mL)
Storage And Handling
ACUVAIL® (ketorolac tromethamine) Ophthalmic Solution 0.45% is available as a sterile solution supplied in clear, LDPE, single-use vials packaged in 6 foil pouches, 5 vials per pouch:
30 Single-Use Vials 0.4 mL each: NDC 0023-3507-30
60 Single-Use Vials 0.4 mL each: NDA 0023-3507-60
Store at 15°-30° C (59°-86° F). Store the vials in the pouch, protected from light. Fold pouch ends closed.
Revised: 10/2012. Allergan Inc.
Last reviewed on RxList: 11/30/2012
This monograph has been modified to include the generic and brand name in many instances.
Additional Acuvail Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.